Christopher Cabell - Insider Trading & Ownership

Location
C/O Arena Pharmaceuticals, Inc., 6154 Nancy Ridge Drive, San Diego, CA
Summary
The estimated net worth of Christopher Cabell is at least $2.35M dollars as of August 28, 2025. Christopher Cabell is the President & Head of R&D of Inhibikase Therapeutics, Inc. and owns shares of Inhibikase Therapeutics, Inc. (IKT) stock worth about $1.7M. Christopher Cabell is the CMO & Head of R&D of Zura Bio Ltd and owns shares of Zura Bio Ltd (ZURA) stock worth about $648K.
Signature
/s/ Mark Iwicki, attorney-in-fact
All Insider Reports
All Insider Reports

Ownership of Christopher Cabell

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
IKT Inhibikase Therapeutics, Inc. President & Head of R&D $1.7M Feb 21, 2025
ZURA Zura Bio Ltd CMO & Head of R&D $648K May 18, 2023
PULM Pulmatrix, Inc. Director Jan 26, 2023

Insider Transactions Reported by Christopher Cabell:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.